2004
Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community
Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community. Clinical Infectious Diseases 2004, 38: 1754-1760. PMID: 15227623, DOI: 10.1086/421392.Peer-Reviewed Original ResearchConceptsMean CD4 lymphocyte countCD4 lymphocyte countAntiretroviral therapyLymphocyte countCopies/Sustained benefitHuman immunodeficiency virus type 1 RNA levelsActive antiretroviral therapyRetrospective cohort studyLog10 copies/Mu LHAART useCohort studyHIV diseaseLymphocyte responsesPoor outcomeIncarcerated patientsRNA levelsLaboratory dataTherapyCorrectional settingsIncarceration periodsOutcomesPeriod of incarcerationCount
1999
Sex Differences in Longitudinal Human Immunodeficiency Virus Type 1 RNA Levels among Seroconverters
Sterling T, Lyles C, Vlahov D, Astemborski J, Margolick J, Quinn T. Sex Differences in Longitudinal Human Immunodeficiency Virus Type 1 RNA Levels among Seroconverters. The Journal Of Infectious Diseases 1999, 180: 666-672. PMID: 10438353, DOI: 10.1086/314967.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1 RNA levelsHIV-1 seroconvertersSex differencesCopies/mLHIV-1 pathogenesisInjection drug usersCase-control studyTime of seroconversionCross-sectional studyCourse of infectionMale patientsRapid progressorsFemale patientsCopies/Drug usersMale controlsVirus levelsPatientsRNA levelsSeroconvertersWomenMenNonprogressorsSeroconversionProgressors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply